Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8629129 | MILLICENT | Pharmaceutical compositions |
Aug, 2028
(5 years from now) | |
US8957054 | MILLICENT | Pharmaceutical compositions |
Jan, 2030
(6 years from now) | |
US8268806 | MILLICENT | Pharmaceutical compositions |
Mar, 2031
(8 years from now) |
Drugs and Companies using PRASTERONE ingredient
Market Authorisation Date: 16 November, 2016
Treatment: Intravaginal prasterone (dehydroepiandrosterone) at a daily dose of 6.5mg for the treatment of dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause
Dosage: INSERT;VAGINAL
8
United States
4
China
3
Singapore
3
Argentina
3
Taiwan, Province of China
3
Korea, Republic of
3
Canada
2
New Zealand
2
Peru
2
EA
2
Japan
2
European Union
1
Portugal
1
Spain
1
Brazil
1
Costa Rica
1
Colombia
1
Norway
1
Philippines
1
Mexico
1
Morocco
1
Hong Kong
1
Tunisia
1
South Africa
1
Saudi Arabia
1
Ukraine
1
Israel
1
Chile
1
Australia
1
Ecuador
1
Denmark
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic